155 related articles for article (PubMed ID: 21133683)
1. First real success for anti-HIV gel: a new start for HIV microbicides?
Ariën KK; Vanham G
Future Microbiol; 2010 Nov; 5(11):1621-3. PubMed ID: 21133683
[No Abstract] [Full Text] [Related]
2. HIV/AIDS. At last, vaginal gel scores victory against HIV.
Cohen J
Science; 2010 Jul; 329(5990):374-5. PubMed ID: 20643914
[No Abstract] [Full Text] [Related]
3. Test of new vaginal microbicide gel show promise for women.
AIDS Read; 2008 Apr; 18(4):165-6. PubMed ID: 18467997
[No Abstract] [Full Text] [Related]
4. HIV prevention in women: next steps.
Vermund SH; Van Damme L
Science; 2011 Jan; 331(6015):284. PubMed ID: 21252332
[No Abstract] [Full Text] [Related]
5. Challenges of introducing vaginal microbicides in India.
Joshi S; Kulkarni V; Paranjape R; Chandhiok N
Indian J Med Res; 2009 May; 129(5):618-9. PubMed ID: 19675395
[No Abstract] [Full Text] [Related]
6. Acceptability of tenofovir gel as a vaginal microbicide by US male participants in a Phase I clinical trial (HPTN 050).
Carballo-Diéguez A; Balán IC; Morrow K; Rosen R; Mantell JE; Gai F; Hoffman S; Maslankowski L; El-Sadr W; Mayer K
AIDS Care; 2007 Sep; 19(8):1026-31. PubMed ID: 17852000
[TBL] [Abstract][Full Text] [Related]
7. A second chance for microbicides.
Baleta A
Lancet; 2007 Jul; 370(9581):17-8. PubMed ID: 17632853
[No Abstract] [Full Text] [Related]
8. Challenges to microbicide introduction in South Africa.
Orner P; Harries J; Cooper D; Moodley J; Hoffman M; Becker J; McGrory E; Dabash R; Bracken H
Soc Sci Med; 2006 Aug; 63(4):968-78. PubMed ID: 16600447
[TBL] [Abstract][Full Text] [Related]
9. Acceptability of a non-woven device for vaginal drug delivery of microbicides or other active agents.
Joanis CL; Hart CW
AIDS Behav; 2010 Jun; 14(3):600-6. PubMed ID: 20049522
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Mayer KH; Maslankowski LA; Gai F; El-Sadr WM; Justman J; Kwiecien A; Mâsse B; Eshleman SH; Hendrix C; Morrow K; Rooney JF; Soto-Torres L;
AIDS; 2006 Feb; 20(4):543-51. PubMed ID: 16470118
[TBL] [Abstract][Full Text] [Related]
11. Reformulated tenofovir gel for use as a dual compartment microbicide.
Dezzutti CS; Rohan LC; Wang L; Uranker K; Shetler C; Cost M; Lynam JD; Friend D
J Antimicrob Chemother; 2012 Sep; 67(9):2139-42. PubMed ID: 22581908
[TBL] [Abstract][Full Text] [Related]
12. Pre-exposure prophylaxis effective.
AIDS Patient Care STDS; 2006 Sep; 20(9):660. PubMed ID: 17036415
[No Abstract] [Full Text] [Related]
13. The need for a "condoms-only" control group in microbicide trials.
Jones H; van de Wijgert J; Kelvin E
Epidemiology; 2003 Jul; 14(4):505; author reply 505-6. PubMed ID: 12843779
[No Abstract] [Full Text] [Related]
14. Specific microbicides in the prevention of HIV infection.
Kelly CG; Shattock RJ
J Intern Med; 2011 Dec; 270(6):509-19. PubMed ID: 21917029
[TBL] [Abstract][Full Text] [Related]
15. African trial of HIV drug disappoints.
AIDS Read; 2008 Apr; 18(4):166. PubMed ID: 18467998
[No Abstract] [Full Text] [Related]
16. Trials begin on HIV gel for women.
AIDS Read; 2007 Aug; 17(8):421-2. PubMed ID: 17722252
[No Abstract] [Full Text] [Related]
17. Differentiating normal from abnormal rates of genital epithelial findings in vaginal microbicide trials.
van de Wijgert JH; Kilmarx PH; Jones HE; Karon JM; Chaikummao S
Contraception; 2008 Feb; 77(2):122-9. PubMed ID: 18226677
[TBL] [Abstract][Full Text] [Related]
18. To tell or not to tell: male partner engagement in a Phase 3 microbicide efficacy trial in South Africa.
Kelly CA; Friedland BA; Morar NS; Katzen LL; Ramjee G; Mokgatle MM; Ahmed K
Cult Health Sex; 2015; 17(8):1004-20. PubMed ID: 25913101
[TBL] [Abstract][Full Text] [Related]
19. Uptake of biomedical interventions for prevention of sexually transmitted HIV.
Abbas UL
Curr Opin HIV AIDS; 2011 Mar; 6(2):114-8. PubMed ID: 21505385
[TBL] [Abstract][Full Text] [Related]
20. Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial.
Mureithi MW; Poole D; Naranbhai V; Reddy S; Mkhwanazi NP; Sibeko S; Werner L; Abdool Karim Q; Abdool Karim S; Ndung'u T; Altfeld M;
J Acquir Immune Defic Syndr; 2012 Jun; 60(2):124-7. PubMed ID: 22362152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
